Systems Biology Ireland

ucd.ie

SBI established in 2009 under the Science Foundation Ireland CSET programme has successfully developed an integrated mathematical modelling and experimental research programme focusing on the design of new therapeutic approaches to cancer, degenerative and inflammatory diseases based on a systems level, mechanistic understanding of cellular signal transduction networks. SBI is one of the few centres in Europe with the necessary in house expertise, technologies and capabilities to apply systems biology approaches to mammalian models. It’s recognition internationally within the field of systems biology led to the Centre’s invited participation in three large European funded consortia initiatives in 2012 namely the ITFoM, CASyM and ISBE, the last of which is included on the ESFRI 2010 Roadmap.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

MODERNA AND ALDEVRON ANNOUNCE EXPANDED COLLABORATION FOR MRNA VACCINE AND THERAPEUTIC PIPELINE

Moderna, Aldevron | May 25, 2021

news image

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Aldevron, LLC, the leading provider of high-quality plasmid DNA, mRNA, and recombinant proteins used for vaccines, gene and cell therapy, gene editing, and diagnostic applications, have announced an expanded collaboration in support of the Moderna COVID-19 Vaccine and additional programs in mRNA therapeutics and vaccines. Aldevron will specifically provide plasmid DNA to act as th...

Read More

DIVERSE BIOTECH ANNOUNCES ORPHAN-DRUG DESIGNATION FOR TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA

Diverse Biotech | May 04, 2020

news image

Diverse Biotech, Inc. www.diversebiotech.com has announced the U.S. Food & Drug Administration (FDA) has granted an orphan-drug designation request for one of its investigational new therapies for treatment of newly diagnosed glioblastoma, in conjunction with standard treatment, following adjuvant combined chemo-radiation. Orphan designation qualifies the sponsor of the drug for various development incentives of the ODA, (Orphan Drug Act) including tax credits for qualified clinical te...

Read More

CG ONCOLOGY ANNOUNCES LICENSE AND COMMERCIALIZATION AGREEMENT WITH KISSEI PHARMACEUTICAL CO., LTD. FOR CG0070 IN JAPAN AND OTHER ASIAN COUNTRIES

BioSpace | March 27, 2020

news image

CG Oncology, Inc. has announced today an exclusive license, development and commercialization agreement with Kissei Pharmaceutical Co., Ltd. ("Kissei") for its oncolytic immunotherapy drug CG0070 for Japan, South Korea, Taiwan and other Asian countries with the exception of China. CG Oncology has completed an investigational Phase 2 study of CG0070 in the United States in patients with BCG-unresponsive, non-muscle-invasive bladder cancer (NMIBC). In addition, CG Oncology is studying th...

Read More

INDUSTRIAL IMPACT, MEDICAL

LABCENTRAL IGNITE LAUNCHES IGNITEVC TO ACCELERATE DIVERSITY AND INCLUSION IN LIFE SCIENCES VENTURE CAPITAL AND INNOVATOR COMPANIES

Prnewswire | April 27, 2023

news image

LabCentral Ignite, a platform dedicated to advancing racial, gender and other representation and opportunity within the life sciences field, today launched IgniteVC in partnership with the Bioscience & Investor Inclusion Group (BIIG). BIIG is a grassroots effort driven by leaders from venture capital (VC) firms and startups. The new initiative aims to cultivate a highly inclusive life sciences venture capital community and support the growth of more diverse and inclusive portfolio comp...

Read More
news image

CELL AND GENE THERAPY

MODERNA AND ALDEVRON ANNOUNCE EXPANDED COLLABORATION FOR MRNA VACCINE AND THERAPEUTIC PIPELINE

Moderna, Aldevron | May 25, 2021

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Aldevron, LLC, the leading provider of high-quality plasmid DNA, mRNA, and recombinant proteins used for vaccines, gene and cell therapy, gene editing, and diagnostic applications, have announced an expanded collaboration in support of the Moderna COVID-19 Vaccine and additional programs in mRNA therapeutics and vaccines. Aldevron will specifically provide plasmid DNA to act as th...

Read More
news image

DIVERSE BIOTECH ANNOUNCES ORPHAN-DRUG DESIGNATION FOR TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA

Diverse Biotech | May 04, 2020

Diverse Biotech, Inc. www.diversebiotech.com has announced the U.S. Food & Drug Administration (FDA) has granted an orphan-drug designation request for one of its investigational new therapies for treatment of newly diagnosed glioblastoma, in conjunction with standard treatment, following adjuvant combined chemo-radiation. Orphan designation qualifies the sponsor of the drug for various development incentives of the ODA, (Orphan Drug Act) including tax credits for qualified clinical te...

Read More
news image

CG ONCOLOGY ANNOUNCES LICENSE AND COMMERCIALIZATION AGREEMENT WITH KISSEI PHARMACEUTICAL CO., LTD. FOR CG0070 IN JAPAN AND OTHER ASIAN COUNTRIES

BioSpace | March 27, 2020

CG Oncology, Inc. has announced today an exclusive license, development and commercialization agreement with Kissei Pharmaceutical Co., Ltd. ("Kissei") for its oncolytic immunotherapy drug CG0070 for Japan, South Korea, Taiwan and other Asian countries with the exception of China. CG Oncology has completed an investigational Phase 2 study of CG0070 in the United States in patients with BCG-unresponsive, non-muscle-invasive bladder cancer (NMIBC). In addition, CG Oncology is studying th...

Read More
news image

INDUSTRIAL IMPACT, MEDICAL

LABCENTRAL IGNITE LAUNCHES IGNITEVC TO ACCELERATE DIVERSITY AND INCLUSION IN LIFE SCIENCES VENTURE CAPITAL AND INNOVATOR COMPANIES

Prnewswire | April 27, 2023

LabCentral Ignite, a platform dedicated to advancing racial, gender and other representation and opportunity within the life sciences field, today launched IgniteVC in partnership with the Bioscience & Investor Inclusion Group (BIIG). BIIG is a grassroots effort driven by leaders from venture capital (VC) firms and startups. The new initiative aims to cultivate a highly inclusive life sciences venture capital community and support the growth of more diverse and inclusive portfolio comp...

Read More